JD001
/ Beijing JD Biotech, Xuzhou Medical University
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 22, 2023
Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies
(clinicaltrials.gov)
- P1 | N=12 | Recruiting | Sponsor: Xuzhou Medical University
New P1 trial • Acute Lymphocytic Leukemia • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19
1 to 1
Of
1
Go to page
1